Mechanisms of anemia in CKD

Journal of the American Society of Nephrology

Volumn 23, Issue 10, 2012, Pages 1631-1634

  Babitt, Jodie L ^a   Lin, Herbert Y ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEPCIDIN; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); DIAGNOSTIC TEST; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ERYTHROPOIESIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; INFECTION; IRON ABSORPTION; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON STORAGE; KIDNEY CLEARANCE; LIVER CELL; MORTALITY; PATHOPHYSIOLOGY; PHAGOCYTOSIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; RISK FACTOR; TISSUE INJURY; TRANSFERRIN BLOOD LEVEL; UREMIA;

EID: 84867178552     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011111078     Document Type: Article

References (41)

1. Bright R: Cases and observations: Illustrative of renal disease accompanied by the secretion of albuminous urine. Guys Hosp Rep 1: 338, 1836
2. KDOQINational Kidney Foundation: KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis 47 [Suppl 3]: S11-S145, 2006
3. Erslev A: Humoral regulation of red cell production. Blood 8: 349-357, 1953
4. Jacobson LO, Goldwasser E, Fried W, Plzak L: Role of the kidney in erythropoiesis. Nature 179: 633-634, 1957
5. Miyake T, Kung CK, Goldwasser E: Purification of human erythropoietin. J Biol Chem 252: 5558-5564, 1977 (Pubitemid 8167007)
6. Lin FK, Suggs S, Lin CH, Browne JK, Smalling R, Egrie JC, Chen KK, Fox GM, Martin F, Stabinsky Z, Badrawi SM, Lai PH, Goldwasser E: Cloning and expression of the human erythropoietin gene. ProcNatl Acad Sci USA 82: 7580-7584, 1985 (Pubitemid 16204391)
7. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, Seehra J, Jones SS, Hewick R, Fritsch EF, Kawakita M, Shimizu T, Miyake T: Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 313: 806-810, 1985 (Pubitemid 15130833)
8. Cotes PM: Immunoreactive erythropoietin in serum. I. Evidence for the validity of the assay method and the physiological relevance of estimates. Br J Haematol 50: 427-438, 1982
9. McGonigle RJ, Wallin JD, Shadduck RK, Fisher JW: Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 25: 437-444, 1984 (Pubitemid 14142834)
10. Garcia JF, Ebbe SN, Hollander L, Cutting HO, Miller ME, Cronkite EP: Radioimmunoassay of erythropoietin: Circulating levels in normal and polycythemic human beings. J Lab Clin Med 99: 624-635, 1982 (Pubitemid 12074797)
11. Sherwood JB, Carmichael LD, Goldwasser E: The heterogeneity of circulating human serum erythropoietin. Endocrinology 122: 1472-1477, 1988 (Pubitemid 18091980)
12. Cotes PM, Tam RC, Reed P, Hellebostad M: An immunological cross-reactant of erythropoietin in serum whichmay invalidate EPO radioimmunoassay. Br J Haematol 73: 265-268, 1989 (Pubitemid 19256123)
13. Eschbach JW: The anemia of chronic renal failure: Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 35: 134-148, 1989
14. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM: Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2: 1175-1178, 1986
15. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316: 73-78, 1987 (Pubitemid 17052741)
16. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584-590, 1998 (Pubitemid 28385655)
17. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D: Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16: 2180-2189, 2005 (Pubitemid 41716451)
18. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
19. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 361: 2019-2032, 2009
20. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetinalpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
21. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. NEngl J Med 363: 1146-1155, 2010
22. Bennett CL, Becker PS, Kraut EH, Samaras AT, West DP: Intersecting guidelines: Administering erythropoiesis-stimulating agents to chronic kidney disease patients with cancer. Semin Dial 22: 1-4, 2009
23. Besarab A, Ayyoub F: Anemia in renal disease. In: Diseases of the Kidney and Urinary Tract, edited by Schrier RW, 8th Ed., Philadelphia, Lippincott Williams and Wilkins, 2007, pp 2406-2430
24. Eschbach JW Jr, Funk D, Adamson J, Kuhn I, Scribner BH, Finch CA: Erythropoiesis in patients with renal failure undergoing chronic dialysis. N Engl J Med 276: 653-658, 1967
25. Vos FE, Schollum JB, Coulter CV, Doyle TC, Duffull SB, Walker RJ: Red blood cell survival in long-term dialysis patients. Am J Kidney Dis 58: 591-598, 2011
26. Babitt JL, Lin HY: Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am J Kidney Dis 55: 726-741, 2010
27. Fudin R, Jaichenko J, Shostak A, Bennett M, Gotloib L: Correction of uremic iron deficiency anemia in hemodialyzed patients: A prospective study. Nephron 79: 299-305, 1998 (Pubitemid 28310335)
28. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50: 1694-1699, 1996 (Pubitemid 26364277)
29. Markowitz GS, Kahn GA, Feingold RE, Coco M, Lynn RI: An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 48: 34-40, 1997 (Pubitemid 27312084)
30. Krause A, Neitz S, Mägert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, Adermann K: LEAP-1, a novel highly disul fide-bonded human peptide, exhibits antimicrobial activity. FEBS Lett 480: 147-150, 2000
31. Park CH, Valore EV, Waring AJ, Ganz T: Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276: 7806-7810, 2001
32. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loréal O: A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. JBiol Chem 276: 7811-7819, 2001
33. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306: 2090-2093, 2004 (Pubitemid 40007660)
34. Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M: Immunoassay for human serum hepcidin. Blood 112: 4292-4297, 2008
35. Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman RS, Maxwell PH, Choi P: Plasma hepcidin levels are elevated but responsive to erythropoietin therapy in renal disease. Kidney Int 75: 976-981, 2009
36. Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB: Hepcidin - a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 4: 1051-1056, 2009
37. Kroot JJ, Kemna EH, Bansal SS, Busbridge M, Campostrini N, Girelli D, Hider RC, Koliaraki V, Mamalaki A, Olbina G, Tomosugi N, Tselepis C, Ward DG, Ganz T, Hendriks JC, Swinkels DW: Results of the first international round robin for the quantification of urinary and plasma hepcidin assays: Need for standardization. Haematologica 94: 1748-1752, 2009
38. Sun CC, Vaja V, Babitt JL, Lin HY: Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of in flammation. Am J Hematol 87: 392-400, 2012
39. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, Winters A, Juan T, Li H, Begley CG, Molineux G: Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation induced anemia. Blood 115: 3616-3624, 2010
40. Steinbicker AU, Sachidanandan C, Vonner AJ, Yusuf RZ, Deng DY, Lai CS, Rauwerdink KM, Winn JC, Saez B, Cook CM, Szekely BA, Roy CN, Seehra JS, Cuny GD, Scadden DT, Peterson RT, Bloch KD, Yu PB: Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation. Blood 117: 4915-4923, 2011
41. Theurl I, Schroll A, Sonnweber T, Nairz M, Theurl M, Willenbacher W, Eller K, Wolf D, Seifert M, Sun CC, Babitt JL, Hong CC, Menhall T, Gearing P, Lin HY, Weiss G: Pharmacologic inhibition of hepcidin expression reverses anemia of chronic disease in rats. Blood 118: 4977-4984, 2011